Abstract
Cancer vaccines based on dendritic cells (DCs) have been among the most vigorously studied new cancer therapies during the last decade. Although DCs, the most potent antigen-presenting cells in the body, can be loaded with tumor antigens through varying approaches, such as pulsing and gene transfer, DC-tumor fusion represents the most effective way of engaging DCs with tumor antigens. A significant amount of effort has been given to DC-tumor fusion vaccines, yet in most cases the clinical responses have been discouraging. Therefore, further improvement of this promising cancer therapy is urgently required in order to optimize its clinical efficacy. In this review, we briefly summarize the history and current status of DC-tumor fusion vaccines. Then, we focus on discussions of the technology and the clinical applications of the dendritoma vaccine, a highly purified DC-tumor cell vaccine that uniquely presents a tumors entire antigen diversity.
Keywords: Dendritic cells, cancer vaccine, immunotherapy, dendritoma, cell fusion
Current Cancer Therapy Reviews
Title: Dendritoma Vaccine for Cancer: A Hopeful Approach
Volume: 5 Issue: 2
Author(s): Yanzhang Wei, Jinhua Li and Thomas E. Wagner
Affiliation:
Keywords: Dendritic cells, cancer vaccine, immunotherapy, dendritoma, cell fusion
Abstract: Cancer vaccines based on dendritic cells (DCs) have been among the most vigorously studied new cancer therapies during the last decade. Although DCs, the most potent antigen-presenting cells in the body, can be loaded with tumor antigens through varying approaches, such as pulsing and gene transfer, DC-tumor fusion represents the most effective way of engaging DCs with tumor antigens. A significant amount of effort has been given to DC-tumor fusion vaccines, yet in most cases the clinical responses have been discouraging. Therefore, further improvement of this promising cancer therapy is urgently required in order to optimize its clinical efficacy. In this review, we briefly summarize the history and current status of DC-tumor fusion vaccines. Then, we focus on discussions of the technology and the clinical applications of the dendritoma vaccine, a highly purified DC-tumor cell vaccine that uniquely presents a tumors entire antigen diversity.
Export Options
About this article
Cite this article as:
Wei Yanzhang, Li Jinhua and Wagner E. Thomas, Dendritoma Vaccine for Cancer: A Hopeful Approach, Current Cancer Therapy Reviews 2009; 5 (2) . https://dx.doi.org/10.2174/157339409788166724
DOI https://dx.doi.org/10.2174/157339409788166724 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Current Management of Obstetric Fistula: Implication for the Low Resource Areas
Current Women`s Health Reviews Transductional Targeting with Recombinant Adenovirus Vectors
Current Gene Therapy The Use of Technetium-99m Radiolabeled Human Antimicrobial Peptides for Infection Specific Imaging
Mini-Reviews in Medicinal Chemistry Exploiting Cancer Metal Metabolism using Anti-Cancer Metal- Binding Agents
Current Medicinal Chemistry Phyto-Phospholipid Complexation as a Novel Drug Delivery System for Management of Cancer with Better Bioavailability: Current Perspectives and Future Prospects
Anti-Cancer Agents in Medicinal Chemistry The Role of JNK Signalling in Responses to Oxidative DNA Damage
Current Drug Targets Overcoming Resistance of Glioblastoma to Conventional Cytotoxic Therapies by the Addition of PARP Inhibitors
Anti-Cancer Agents in Medicinal Chemistry 7-O-aminoalkyl-2,3-dehydrosilibinins: Synthesis and in vitro Anti-cancer Efficacy
Anti-Cancer Agents in Medicinal Chemistry Multiple Sclerosis: Pathogenesis and Treatment
Current Neuropharmacology Thiazolidinediones and Type 2 Diabetes: From Cellular Targets to Cardiovascular Benefit
Current Drug Targets Individualized Treatment Planning in Oncology: Role of PET and Radiolabelled Anticancer Drugs in Predicting Tumour Resistance
Current Pharmaceutical Design Infringement of the Barriers of Cancer Via Dietary Phytoconstituents Capsaicin Through Novel Drug Delivery System
Current Drug Delivery Targeting Notch Pathway in Cancer Diagnostics and Therapeutics: An Emerging Approach
Recent Patents on Anti-Cancer Drug Discovery Triple Negative Breast Cancer - BCL2 in Prognosis and Prediction. Review
Current Drug Targets PTD/CPP Peptide-Mediated Delivery of siRNAs
Current Pharmaceutical Design Fluorine-18 Labeled Amino Acids for Oncologic Imaging with Positron Emission Tomography
Current Topics in Medicinal Chemistry Antineoplastic Potential of Medicinal Plants
Recent Patents on Biotechnology Role of Mismatch Repair and MGMT in Response to Anticancer Therapies
Anti-Cancer Agents in Medicinal Chemistry The Holy Grail of Polymer Therapeutics for Cancer Therapy: An Overview on the Pharmacokinetics and Bio Distribution
Current Drug Metabolism Peroxynitrite-Mediated Structural Changes in Histone H2A: Biochemical and Biophysical Analysis
Protein & Peptide Letters